Literature DB >> 25183787

Advanced magnetic resonance imaging of the physical processes in human glioblastoma.

Jayashree Kalpathy-Cramer1, Elizabeth R Gerstner2, Kyrre E Emblem1,3, Ovidiu Andronesi1, Bruce Rosen1.   

Abstract

The most common malignant primary brain tumor, glioblastoma multiforme (GBM) is a devastating disease with a grim prognosis. Patient survival is typically less than two years and fewer than 10% of patients survive more than five years. Magnetic resonance imaging (MRI) can have great utility in the diagnosis, grading, and management of patients with GBM as many of the physical manifestations of the pathologic processes in GBM can be visualized and quantified using MRI. Newer MRI techniques such as dynamic contrast enhanced and dynamic susceptibility contrast MRI provide functional information about the tumor hemodynamic status. Diffusion MRI can shed light on tumor cellularity and the disruption of white matter tracts in the proximity of tumors. MR spectroscopy can be used to study new tumor tissue markers such as IDH mutations. MRI is helping to noninvasively explore the link between the molecular basis of gliomas and the imaging characteristics of their physical processes. We, here, review several approaches to MR-based imaging and discuss the potential for these techniques to quantify the physical processes in glioblastoma, including tumor cellularity and vascularity, metabolite expression, and patterns of tumor growth and recurrence. We conclude with challenges and opportunities for further research in applying physical principles to better understand the biologic process in this deadly disease. See all articles in this Cancer Research section, "Physics in Cancer Research." ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25183787      PMCID: PMC4155518          DOI: 10.1158/0008-5472.CAN-14-0383

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  162 in total

1.  Multiparametric imaging of tumor response to therapy.

Authors:  Anwar R Padhani; Kenneth A Miles
Journal:  Radiology       Date:  2010-08       Impact factor: 11.105

2.  Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies.

Authors:  Caleb Roberts; Basma Issa; Andrew Stone; Alan Jackson; John C Waterton; Geoffrey J M Parker
Journal:  J Magn Reson Imaging       Date:  2006-04       Impact factor: 4.813

Review 3.  Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

Authors:  P S Tofts
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

4.  MR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas.

Authors:  Xiang Liu; Wei Tian; Balasubramanya Kolar; Gabrielle A Yeaney; Xing Qiu; Mahlon D Johnson; Sven Ekholm
Journal:  Neuro Oncol       Date:  2011-02-04       Impact factor: 12.300

5.  Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

Authors:  Daniel A Hamstra; Thomas L Chenevert; Bradford A Moffat; Timothy D Johnson; Charles R Meyer; Suresh K Mukherji; Douglas J Quint; Stephen S Gebarski; Xiaoying Fan; Christina I Tsien; Theodore S Lawrence; Larry Junck; Alnawaz Rehemtulla; Brian D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-02       Impact factor: 11.205

6.  NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.

Authors:  David M Peereboom; Manmeet S Ahluwalia; Xiaobu Ye; Jeffrey G Supko; Sarah L Hilderbrand; Surasak Phuphanich; L Burt Nabors; Myrna R Rosenfeld; Tom Mikkelsen; Stuart A Grossman
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

7.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

8.  Identification of noninvasive imaging surrogates for brain tumor gene-expression modules.

Authors:  Maximilian Diehn; Christine Nardini; David S Wang; Susan McGovern; Mahesh Jayaraman; Yu Liang; Kenneth Aldape; Soonmee Cha; Michael D Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

9.  Incorporating contrast agent diffusion into the analysis of DCE-MRI data.

Authors:  Martin Pellerin; Thomas E Yankeelov; Martin Lepage
Journal:  Magn Reson Med       Date:  2007-12       Impact factor: 4.668

10.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Paul Mulholland; Bart Neyns; L Burt Nabors; Mario Campone; Antje Wick; Warren Mason; Tom Mikkelsen; Surasak Phuphanich; Lynn S Ashby; John Degroot; Rao Gattamaneni; Lawrence Cher; Mark Rosenthal; Franz Payer; Juliane M Jürgensmeier; Rakesh K Jain; A Gregory Sorensen; John Xu; Qi Liu; Martin van den Bent
Journal:  J Clin Oncol       Date:  2013-08-12       Impact factor: 44.544

View more
  57 in total

Review 1.  Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Authors:  Mark S Shiroishi; Jerrold L Boxerman; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-09-12       Impact factor: 12.300

2.  Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of Glioblastoma.

Authors:  Derek Reichel; Bien Sagong; James Teh; Yi Zhang; Shawn Wagner; Hongqiang Wang; Leland W K Chung; Pramod Butte; Keith L Black; John S Yu; J Manuel Perez
Journal:  ACS Nano       Date:  2020-06-23       Impact factor: 15.881

Review 3.  Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.

Authors:  C von Neubeck; A Seidlitz; H H Kitzler; B Beuthien-Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-07-10       Impact factor: 3.039

4.  Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques.

Authors:  Luke Macyszyn; Hamed Akbari; Jared M Pisapia; Xiao Da; Mark Attiah; Vadim Pigrish; Yingtao Bi; Sharmistha Pal; Ramana V Davuluri; Laura Roccograndi; Nadia Dahmane; Maria Martinez-Lage; George Biros; Ronald L Wolf; Michel Bilello; Donald M O'Rourke; Christos Davatzikos
Journal:  Neuro Oncol       Date:  2015-07-16       Impact factor: 12.300

5.  Imaging the intratumoral-peritumoral extracellular pH gradient of gliomas.

Authors:  Daniel Coman; Yuegao Huang; Jyotsna U Rao; Henk M De Feyter; Douglas L Rothman; Christoph Juchem; Fahmeed Hyder
Journal:  NMR Biomed       Date:  2016-01-11       Impact factor: 4.044

6.  Cranial fixation plates in cerebral magnetic resonance imaging: a 3 and 7 Tesla in vivo image quality study.

Authors:  Bixia Chen; Tobias Schoemberg; Oliver Kraff; Philipp Dammann; Andreas K Bitz; Marc Schlamann; Harald H Quick; Mark E Ladd; Ulrich Sure; Karsten H Wrede
Journal:  MAGMA       Date:  2016-03-30       Impact factor: 2.310

7.  Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.

Authors:  Karen E Parrish; Ling Cen; James Murray; David Calligaris; Sani Kizilbash; Rajendar K Mittapalli; Brett L Carlson; Mark A Schroeder; Julieann Sludden; Alan V Boddy; Nathalie Y R Agar; Nicola J Curtin; William F Elmquist; Jann N Sarkaria
Journal:  Mol Cancer Ther       Date:  2015-10-05       Impact factor: 6.261

8.  Multimodality imaging and mathematical modelling of drug delivery to glioblastomas.

Authors:  Ahmed Boujelben; Michael Watson; Steven McDougall; Yi-Fen Yen; Elizabeth R Gerstner; Ciprian Catana; Thomas Deisboeck; Tracy T Batchelor; David Boas; Bruce Rosen; Jayashree Kalpathy-Cramer; Mark A J Chaplain
Journal:  Interface Focus       Date:  2016-10-06       Impact factor: 3.906

9.  Over-expression of TOP2A as a prognostic biomarker in patients with glioma.

Authors:  Tianmin Zhou; Yan Wang; Dongmeng Qian; Qing Liang; Bin Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

10.  Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.

Authors:  Elavarasan Subramani; Marina Radoul; Chloe Najac; Georgios Batsios; Abigail R Molloy; Donghyun Hong; Anne Marie Gillespie; Romelyn Delos Santos; Pavithra Viswanath; Joseph F Costello; Russell O Pieper; Sabrina M Ronen
Journal:  Cancer Res       Date:  2020-09-21       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.